StockNews.com Initiates Coverage on Revance Therapeutics (NASDAQ:RVNC)
Stock analysts at StockNews.com started coverage on shares of Revance Therapeutics (NASDAQ:RVNC – Get Free Report) in a report issued on Saturday. The firm set a “hold” rating on the biopharmaceutical company’s stock. Several other equities analysts have also recently issued reports on RVNC. Mizuho decreased their price objective on Revance Therapeutics from $6.66 to […]
Stock analysts at StockNews.com started coverage on shares of Revance Therapeutics (NASDAQ:RVNC – Get Free Report) in a report issued on Saturday. The firm set a “hold” rating on the biopharmaceutical company’s stock. Several other equities analysts have also recently issued reports on RVNC. Mizuho decreased their price objective on Revance Therapeutics from $6.66 to […]
